At SXSW, two FDA observers said stability is returning to the agency after painful DOGE personnel cuts last year, though it's not equal across divisions. And now, AI tools are being adopted across the board to improve efficiency.
By James E. Valentine* - Whether you call it “patient advocacy,” “patient engagement,” or maybe something a little fancier, in recent years incorporating the patient perspective has become a hot topic issue for FDA and drug developers alike. As FDA...
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.